NCT02451540View on ClinicalTrials.gov

Evaluation of the Effect of Roflumilast in Hyperinflated COPD Patients Using Functional Respiratory Imaging

PHASE2TerminatedINTERVENTIONAL
Enrollment

13

Participants

Timeline

Start Date

September 30, 2015

Primary Completion Date

August 31, 2017

Study Completion Date

August 31, 2017

Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
RADIATION

HRCT scan

HRCT scan of thorax, at baseline and after 3 months

DRUG

Placebo of Roflumilast

Placebo, once a day in the morning during 3 months

DRUG

Roflumilast

Roflumilast, once a day in the morning during 3 months

Trial Locations (1)

2650

University Hospital of Antwerp, Edegem

Sponsors

Lead Sponsor

FLUIDDA nv
All Listed Sponsors
lead

FLUIDDA nv

INDUSTRY